Table 2

Baseline Characteristics of Studies Included in the Meta-Analysis

First Author (Ref. #)YearBaseline CharacteristicsIndicationsUnderlying Heart Disease
NMaleAge (yrs)Ejection Fraction (%)Primary PreventionSecondary PreventionCardiomyopathy (Ischemic, Nonischemic, Dilated)CAD or Ischemic Heart DiseaseHCM
S-ICDTV-ICDS-ICDTV-ICDS-ICDTV-ICDS-ICDTV-ICDS-ICDTV-ICDS-ICDTV-ICDS-ICDTV-ICDS-ICDTV-ICDS-ICDTV-ICD
Köbe et al. (14)20136969505045.7 ± 15.747.7 ± 14.746.2 ± 15.640.6 ± 15.94134283525321113104
Brouwer et al. (11)20161401408487414250499386¾¾54713338¾¾
Honarbakhsh et al. (10)20166969525235 ± 1340 ± 1057 ± 1558 ± 13565613131010¾¾4142
Friedman et al. (12)20161,9203,8401,2932,6095453.931.231.3¾¾¾¾8461,6778791,747123242
Mithani et al. (13)20167171¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾

Values are n or mean ± SD unless otherwise indicated.

CAD = coronary artery disease; HCM = hypertrophic cardiomyopathy; S-ICD = subcutaneous implantable cardioverter-defibrillator; TV-ICD = transvenous implantable cardioverter-defibrillator.

  • Baseline characteristics of the participants were statistically not significant between the S-ICD and TV-ICD groups.